Investors: Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital
Neomorph closed a $100M Series B led by Deerfield Management to advance NEO-811 molecular glue degrader in Phase 1/2 trials for renal cancer, with backing from Regeneron Ventures and Dana-Farber's Binney Street Capital.
View article →